Literature DB >> 1676566

Resistance to chloroquine by Plasmodium vivax in Irian Jaya, Indonesia.

J K Baird1, H Basri, M J Bangs, B Subianto, L C Patchen, S L Hoffman.   

Abstract

Evidence of emerging resistance to chloroquine by Plasmodium vivax is described from Irian Jaya (Indonesian New Guinea). Sixteen of 24 residents in the village of Arso PIR II taking supervised weekly chloroquine prophylaxis (5 mg base/kg) had asexual parasitemia with P. vivax at least once during eight weeks of surveillance. An American working in the same village developed symptomatic P. vivax parasitemia despite chloroquine prophylaxis. Five days after therapy with 600 mg chloroquine base, the asexual parasitemia in the American increased 40-fold, but cleared after treatment with 1,500 mg chloroquine base. Serum samples were not available from many of the cases, but six local residents and the American had serum levels of chloroquine in excess of the ordinarily suppressive 15 ng/ml at the time of their asexual parasitemias (16-70 ng/ml). The weekly 300 mg base tablet of chloroquine, which has been the standard for prophylaxis against malaria for more than 40 years, was not effective against P. vivax in Arso PIR, Irian Jaya.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1676566     DOI: 10.4269/ajtmh.1991.44.547

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  79 in total

Review 1.  The evolution of tafenoquine--antimalarial for a new millennium?

Authors:  W Peters
Journal:  J R Soc Med       Date:  1999-07       Impact factor: 5.344

Review 2.  Chloroquine resistance in Plasmodium vivax.

Authors:  J Kevin Baird
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

3.  In vitro activity of pyronaridine against multidrug-resistant Plasmodium falciparum and Plasmodium vivax.

Authors:  R N Price; J Marfurt; F Chalfein; E Kenangalem; K A Piera; E Tjitra; N M Anstey; B Russell
Journal:  Antimicrob Agents Chemother       Date:  2010-09-27       Impact factor: 5.191

4.  In vitro anti-malarial drug susceptibility of temperate Plasmodium vivax from central China.

Authors:  Feng Lu; Qi Gao; Kesinee Chotivanich; Hui Xia; Jun Cao; Rachanee Udomsangpetch; Liwang Cui; Jetsumon Sattabongkot
Journal:  Am J Trop Med Hyg       Date:  2011-08       Impact factor: 2.345

5.  Amplification of pvmdr1 associated with multidrug-resistant Plasmodium vivax.

Authors:  R Suwanarusk; M Chavchich; B Russell; A Jaidee; F Chalfein; M Barends; B Prasetyorini; E Kenangalem; K A Piera; U Lek-Uthai; N M Anstey; E Tjitra; F Nosten; Q Cheng; R N Price
Journal:  J Infect Dis       Date:  2008-11-15       Impact factor: 5.226

Review 6.  A pre-emptive strike against malaria's stealthy hepatic forms.

Authors:  Dominique Mazier; Laurent Rénia; Georges Snounou
Journal:  Nat Rev Drug Discov       Date:  2009-11       Impact factor: 84.694

7.  Plasmodium vivax resistance to chloroquine in Madagascar: clinical efficacy and polymorphisms in pvmdr1 and pvcrt-o genes.

Authors:  Céline Barnadas; Arsène Ratsimbasoa; Magali Tichit; Christiane Bouchier; Martial Jahevitra; Stéphane Picot; Didier Ménard
Journal:  Antimicrob Agents Chemother       Date:  2008-09-22       Impact factor: 5.191

Review 8.  Plasmodium vivax treatments: what are we looking for?

Authors:  Ric N Price; Nicholas M Douglas; Nicholas M Anstey; Lorenz von Seidlein
Journal:  Curr Opin Infect Dis       Date:  2011-12       Impact factor: 4.915

9.  Analysis of the dihydrofolate reductase-thymidylate synthase gene sequences in Plasmodium vivax field isolates that failed chloroquine treatment.

Authors:  Won-Ja Lee; Hyung-Hwan Kim; Yien-Kyoung Choi; Kyung-Mi Choi; Mi-A Kim; Jung-Yeon Kim; Jetsumon Sattabongkot; Youngjoo Sohn; Hyuck Kim; Jong-Koo Lee; Han-Sook Park; Hyeong-Woo Lee
Journal:  Malar J       Date:  2010-11-18       Impact factor: 2.979

Review 10.  Human antiprotozoal therapy: past, present, and future.

Authors:  M Khaw; C B Panosian
Journal:  Clin Microbiol Rev       Date:  1995-07       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.